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We have recently reported the mechanical properties and hydrolytic degradation behavior
of a series of NovoSorb™ biodegradable polyurethanes (PUs) prepared by varying
the hard segment (HS) weight percentage from 60 to 100. In this study, the in vitro
degradation behavior of these PUs with and without extracellular matrix (ECM) coating
was investigated under accelerated hydrolytic degradation (phosphate buffer saline;
PBS/70°C) conditions. The mass loss at different time intervals and the effect of aqueous
degradation products on the viability and growth of human umbilical vein endothelial cells
(HUVEC) were examined. The results showed that PUs with HS 80% and below com-
pletely disintegrated leaving no visual polymer residue at 18weeks and the degradation
medium turned acidic due to the accumulation of products from the soft segment (SS)
degradation. As expected the PU with the lowest HS was the fastest to degrade. The
accumulated degradation products, when tested undiluted, showed viability of about
40% for HUVEC cells. However, the viability was over 80% when the solution was diluted
to 50% and below. The growth of HUVEC cells is similar to but not identical to that
observed with tissue culture polystyrene standard (TCPS). The results from this in vitro
study suggested that the PUs in the series degraded primarily due to the SS degradation
and the cell viability of the accumulated acidic degradation products showed poor viability
to HUVEC cells when tested undiluted, however particles released to the degradation
medium showed cell viability over 80%.
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Introduction
A major driver to develop biodegradable stents is to overcome problems of conventional metallic
stents (scarring, thrombosis, and clotting), as well as to eliminate the need to have a permanent
implant embedded in the vessel as mechanical reinforcement of the vessel may not be needed
once the arterial remodeling and healing have occurred (Heublein et al., 2003; Tsuji et al., 2003).
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Two of the most promising biodegradable stents that have been
tested in human clinical trials are the Igaki-Tamai® and Absorb™
stents. The Igaki-Tamai® stent with a zig zag helical coil design is
made from biodegradable poly--lactic acid (PLLA) and has been
clinically tested (Serruys et al., 2011;Nishio et al., 2012). In the past
3 years, over 60,000 Absorb™ bioresorbable vascular stents have
been implanted, and their short-term relative performance against
metallic stents have been reported but long-term data is needed
before their widespread use (Di Mario and Caiazzo, 2015). Mag-
nesium and its alloys have also been investigated for biodegrad-
able stents but their degradation rate has not been optimized to
acceptable levels (Moravej and Mantovani, 2011). Despite these
developments, new materials with good biocompatibility, ade-
quate mechanical strength during healing and remodeling, as well
as complete degradation of the materials to nontoxic products are
still sought after.
Polyurethanes have been used as drug eluting coatings for
metallic stents, and there is considerable interest to develop a
polyurethane-based biodegradable stent due to their excellent
mechanical properties and good biocompatibility, and the wide
choice of monomers and formulation options available to tailor
polymer structures to meet property and performance specifica-
tions of vascular stents (Rechavia et al., 1998).
Wepreviously reported themechanical properties anddegrada-
tion behavior ofNovoSorb™ series of high strength PUs developed
to explore their application in vascular stents (Sgarioto et al.,
2014). Evaluation of real-time degradation behavior of these PUs
indicated that more than 9months may be required for complete
degradation in vivo. In order to better understand the degradation
of this PU series and the effect of degradation products on cell
viability, an in vitro degradation study was conducted at 70°C.
Considering the in vivo toxicity concerns of PUs in the past (Batich
et al., 1989; Guidoin et al., 1992; Benoit, 1993;Williams, 1995), it is
essential to investigate the cytotoxicity of biodegradable PUs and
their degradation products.
Biodegradable PUs have been investigated extensively for
biomedical application, in particular as scaffolds in regenerative
medicine therapies, and several studies have reported on the
degradation of PUs specifically designed to be biodegradable (de
Groot et al., 1997; Dupret et al., 1999; Tuominen et al., 2002;
Gunatillake et al., 2006; van Minnen et al., 2006; Yilgor and Yil-
gor, 2007; Guelcher, 2008). Most of the studies have focused on
understanding the rate of degradation under in vitro conditions,
generally for softer grades of PUs (lowHS content). Hafeman et al.
(2011) have reported PUs based on lysine diisocyanate and hex-
amethylene diisocyanate and demonstrated that hydrolytic and
macrophage mediated esterolytic and oxidative mechanisms are
responsible for poly(ester urethane)s degradation. The primary
mode of degradation is hydrolytic where the ester bonds in the
SS degrade to respective α-hydroxy acids. The isolation of degra-
dation products due to HS degradation is reported in this paper,
but the extent of the degradation and the underlying mechanisms
are not clear.
Many of the studies reported in the literature have investigated
softer grades of PUs and the series of PUs reported in this study
have relatively higher proportion of HS, purposely formulated to
achieve high strength for applications such as coronary stents.
The study also aims to understand their degradation behavior
as well as any toxicity associated with degradation products.
Since the degradation is relatively slow in simulated body tem-
perature conditions, we have used accelerated test conditions to
force degradation to yield higher concentration of degradation
products to assess their toxicity. Although in vitro degradation is
not a very good predictor of in vivo degradation since different
mechanisms are operating in vivo, this study helps to understand
the degradation behavior of harder grades of PUs under hydrolytic
conditions and the effect of HS concentration on degradation rate.
The physical changes in the polymer including appearance,
and the effect of degradation products on solution pH and cyto-
toxicity were examined. The effect of HS proportion and ECM
coatings on accelerated degradation was also investigated.We also
investigated the role of ECM proteins such as collagen (Coll) and
fibronectin (Fn) coatings on PU surface to improve endothelial-
ization. This approach has been investigated for other synthetic
polymers (Budd et al., 1989; Gosselin et al., 1996; Walluscheck
et al., 1996; Feugier et al., 2005; Turner et al., 2006; Nagel et al.,
2008) but only few investigations with biodegradable PUs.
Materials and Methods
Polymer Studies
Polymer Preparation
The PU series was developed, synthesized and supplied by Poly-
Novo Biomaterials Pty Ltd. as previously reported (Sgarioto et al.,
2014). Each of the five PUswas synthesized from1,6-hexane diiso-
cyanate (HDI), isophorone diisocyanate (IPDI) and 1,4-butane
diol, while the soft segment (SS) was based a copolymer of -lactic
acid and glycolic acid P(LLA:GA) with MW 1033 with LLA:GA
ratio 90:10. The PUs in the series have a HS ranging from 60 to
100% and were labeled as: 60, 70, 80, 90, and 100% HS. The PUs
were compressionmolded into 100 µmthick films usingDiamond
Fusion® glass plates between 180 and 200°C under a nominal load
of 8 tons cut into 1 cm2 disks. A digital caliper (Fowler Value-
Cal®) was used to measure sample thickness and only 100 10
µm thick films were used. Polymer samples were placed in a
plastic bag (flushed with nitrogen) and stored in a desiccator
at a temperature of approximately 25°C. Polymer samples were
sterilized at Steritech Pty Ltd., Vic. and packaged into zip lock
plastic bags (25 samples per bag) under nitrogen atmosphere and
exposed to 25 kGy of γ-irradiation. The bags were kept sealed in a
desiccator at ambient temperature and only opened immediately
before their use.
Protein Coating
Collagen (Coll, purified bovine Type I collagen, CBPE2, Symatese
S.A.S) and Fibronectin (Fn) (human plasma fibronectin,
11051407, Roche Diagnostics Pty Ltd.) were used in this study
as a single and double-layered coating. Fibronectin was used
at a concentration of 2 µg/mL in PBS (120 ng/cm2), Coll was
used at 1mg/mL dissolved in distilled water (60 µg/cm2)
as per manufacturer’s guidelines. A collagen coating at this
concentration has been shown to enable fibril formation in vitro
(Kreger et al., 2010).
The polymer samples were passively coated following the pro-
tocol previously described by Sgarioto et al. (2012) The Fn solution
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was allowed to adsorb on the TCPS for 45min, at 37°C andwashed
with PBS 3 times for 10min. The Coll was left to adsorb for
10min at RT and then washed twice in PBS for 10min. The colla-
gen+ fibronectin (Coll+ Fn) coating was done similarly except,
Coll was coated first followed by the Fn.
Accelerated Degradation of Polyurethane Series
Accelerated degradation studies were carried out according to a
modified ASTM F 1635 method. Any changes to the solution pH
due to accumulating degradation products were not adjusted to
maintain solution sterility required for subsequent cell viability
studies. Polymer samples (1 cm2 disks) were placed in 18mL glass
vials containing 5mL of 0.1 M PBS at pH 7.4 and incubated in an
oven at 70°C for 18weeks. At pre-defined time points (24 h, 1, 2,
4, 6, 8, 10, 14, 18weeks), 100 µL of the degradation solution was
removed from the test vial and subjected to the toxicity tests. The
pH of the PBS was measured weekly over the 18weeks using a pH
meter (Mettler Toledo™) in a concurrent experiment. The samples
were removed from 70°C bath and left to cool to RT (minimum of
1 h) before pH measurement. The results represent the mean of
three samples SE.
Physical Changes during Accelerated Degradation
A Gel Doc™ XR system was used to demonstrate the physi-
cal change in the polymer during the 18-week period. At pre-
determined time points; 0 h, 24 h, 1, 2, 4, 6, 8, 10, 14, and 18weeks,
the bulk polymer sample that had not yet degraded into soluble
productswas taken from the vial (at 70°C), rinsed in distilledwater
and any surface water was removed with a Kimwipe®. Images of
the polymer sample were taken and data acquired using the com-
puter software programQuantityOne® (version 4.6.7) to show the
physical and structural changes of the polymer during accelerated
degradation. If the sample had degraded into fragments that could
not be easily removed, images were obtained of the sample within
the storage container.
In vitro Cytotoxicity Study (MTT Test)
The cell viability assay using MTT (3-(4,5-dimethylthiazol-2-yl)-
2, 5-diphenyltetrazolium bromide; Invitrogen™) was undertaken
as a measure of the effect of the degrading polymer on cell
proliferation and activity. The effect of HS and ECM on cell
viability was determined by measuring the uptake and reduction
of the tetrazolium salt to an insoluble formazan dye by cellular
microsomal enzymes. To reduce experimental error and improve
seeding efficiency, the wells that lined the perimeter of the 96-
well plate were not used in this experiment. 100 µL of PBS was
placed in each of these wells to create a barrier around the seeded
wells, ensuring that any evaporation that occurred whilst in the
incubator would only occur in the wells containing PBS. The 96-
well micro-titration plates were seeded with 10,000 cells/cm2 and
incubated for 48 h to allow for cell attachment and confluence.
After the incubation the medium was removed and replaced with
50 µL of freshmedium except for a designated column one treated
as control. 100 µL of degradation solution (not diluted in PBS)
was placed into column two and a serial dilution (twofold) of
the degradation solution was carried out until column six. After
24 h of incubation, the media containing degradation solution
was removed, the wells were washed in PBS and 50 µL of fresh
media was added. 5 µL of MTT solution (5mg/mL PBS) was
placed into each well and incubated at 37°C. After 4 h of incu-
bation, 25 µL of the media+MTT solution was removed and
50 µL of dimethyl sulfoxide (DMSO; Sigma-Aldrich©) was added
to each well for cell permeabilization and incubated at 37°C for
10min. Absorption at 540 nm was measured using a microplate
reader (Biorad Laboratories). The percentage of cell activity after
exposure to degradation products was determined by dividing
the absorbance of the wells exposed to degradation products
and of the control well for that sample. Each sample was per-
formed in triplicate and each experiment was repeated three
times. The data represent the mean percentage of cell activity
compared to the control well SE (n= 9). The control well was
composed of all components of the assay except the degradation
solution.
The Toxicity of the Degradation Solution Components
After 18weeks of accelerated degradation, the individual compo-
nents of the PBS degradation solution for 60% HS was separated
and tested for cell activity. The three components of the degrada-
tion solution testedwere; the PBS containing degradation particles
(complete degradation solution), the degradation particles alone
(particles only) and the PBS alone, which is the PBS degradation
solution after the degradation particles were removed. The MTT
assay was used as a measure of the effect of the separated degra-
dation particles for 60% HS after 18weeks of degradation on cell
proliferation and activity.
Ninety-six well microtitration plates were seeded with
10,000 cells/cm2 and incubated for 48 h to allow for cell
attachment and confluence. 200 µL of degradation solution was
removed from the sample vial of which 100 µL was transferred
into a centrifuge tube and subjected to 1,000 RPM for 4min. The
PBS was then removed and the pellet containing degradation
particles was re-suspended in 100 µL of media. The 96-well plate
was then removed from the 37°C oven and the old medium
was replaced with one of the three test solutions; complete
degradation solution, PBS only and the degradation particles
only. The cells were exposed to 100 µL of each test solution for
24 h at 37°C; test solutions removed and the cells washed in PBS,
and 50 µL of media were added to cells in each well. 5 µL of MTT
solution (5mg/mL PBS) was placed into each well and incubated
at 37°C. After 4 h incubation, 25 µL were removed and 50 µL
of DMSO were added, and incubated at 37°C for 10min. The
absorption at 540 nm was measured using a microplate reader
(Biorad Laboratories Inc.). For each experiment, the samples
were tested in triplicate and three identical experiments were
performed. The data represent the mean cell viability of the test
solutions, calculated as a percentage of the total cell viability
found with the control well (no products). The control well was
composed of media and all components of the assay, except one
of the three test solutions which contained PBS.
Data is presented as a digitally enhanced version of the original
figure (editing using the exposure option in Photoshop®). It was
necessary to provide an enhanced version for this figure to correct
the photomicrography lack of contrast and to exaggerate the detail
of interest.
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Growth Curve
Tissue culture polystyrene and the five PUs were seeded with
HUVEC and cultured in a humidified incubator (37°C, 5% CO2)
for 14 days. The endothelial cell growth on each polymer was
tested without an ECM coating. The samples were seeded at a
density of 10,000 cells/cm2. The cells were maintained at 37°C
and the polymer samples were collected after 1, 2, 6, and 10 days
post-seeding. The samples were then rinsed in PBS to remove
nonadherent cells and trypsinized. The proliferation on the coated
and uncoated samples was determined by cell counting using
trypan blue. The reported data represent the average of three
samples.
HUVEC Growth on Extracellular Matrix-Coated
Polyurethane
Coating studies were carried out on 1 cm2 disks, comparing the
proliferation on TCPS with the PU series. The polymer samples
were coated with each of the ECM proteins and the HUVEC
were seeded onto each sample at a density of 20,000 cells/cm2
and maintained at 37°C. After 48 h in culture the samples were
collected, washed with PBS and a second cell count was per-
formed to determine the proliferation of endothelial cells. This
experiment was performed in triplicate and each experiment was
repeated twice. The results represent the mean proliferation SE
of 2 individual experiments (n= 6).
Visual Analysis of Endothelialization
The growth, structure and endothelialization of the ECM-coated
and uncoated polymer surface were examined by fluorescence
microscopy. The polymer series was coated with each of the ECM
proteins and seeded at a density of 20,000 cells/cm2. After 24 h
in culture the cells were washed with PBS and fixed with 4%
PAF, over-night at 4°C. The cells were then washed with PBS
and incubated in the dark at RT in 200 µL of the diluted 2mM
EthD-1 solution (2 µL/mL PBS) and component B of the live/dead
stain (Invitrogen™). After 2 h, the stain was replaced with PBS
and the cells were gently washed three times. The excess PBS was
removed and the polymer sample was transferred onto a glass
slide, mounted and viewed under the fluorescence microscope
(Nikon Eclipse 50i).
Statistical Analysis
The statistical program GraphPad InStat® software was used to
analyze the data. Unless otherwise stated, the data were repre-
sented as the mean SE of nine measurements, corresponding
to three samples of coated PU for each ECM protein, with each
experiment repeated in triplicate. Comparisons of the in vitro
cytotoxicity study across the five polymers, four conditions and
different concentrations were determined by repeated-measures
two-way (mixed model) ANOVA. Comparisons between two
parameters, such as Coll-coated 60% HS at 100 and 50% concen-
tration, were assessed by the Bonferroni post-test. Comparison
of the toxicity of the individual degradation components was
determined by a one-way ANOVA. The Newman-Keuls Multiple
Comparison post-test was used to assess the difference in toxicity
between two parameters, such as PBS only and particles only.
Comparisons between the cell coverage across five HS percent-
ages and four experimental conditions were determined by a
two-way ANOVA. A Bonferroni post-test was used to assess the
endothelialization of two parameters, such as a Coll-coated 60%
HS and Fn-coated 60% HS. The statistical results provided in
the figures (when statistical significance was found) show com-
parisons between the ECM coatings of the same HS percentage
only (e.g., Coll-coated 60% HS and Fn-coated 60% HS), not
comparison between the ECM coating of different HS percentages
(e.g., Coll-coated 60% HS and Fn-coated 70% HS). A p value of:
<0.05 (*) was considered significant; <0.001 (**) was considered
very significant, and <0.0001 (***) was considered extremely
significant.
Results
Physical Changes during Accelerated
Degradation
The percentageweight loss of the degrading polymerwas recorded
to characterize the physical changes that occurred during 18weeks
of degradation. Figure 1 shows that as the HS increased the
effect of degradation on the physical appearance of the polymer
decreased. The 60%HS polymer showed themost obvious change
during accelerated degradation, with a large reduction in size and
structure observed after only 24 h. The small opaque structure that
was observed at 24 h eroded into small aggregates at 1 week, which
continued to reduce in size gradually over the next 7weeks until
it had completely eroded by Week 8.
The polymers with 70 and 80%HS had similar physical changes
during degradation, and identical trends were observed for 90 and
100% HS. The 70 and 80% HS became opaque at 24 h, decreasing
gradually in size every week until Week 4, where the polymers
changed in structure to form aggregates of spherical particles. The
70 and 80% HS had completely eroded into solution after 14 and
18weeks, respectively. The samples with 90 and 100% HS became
opaque after 24 h but retained the original circular, flat shape
despite some reduction is size, presumably due to shrinkage. The
polymer samples gradually decreased in size over several weeks,
until Week 4, where the polymer samples became spherical, and
retained this shape and size until Week 18. The samples that had
completely eroded (to the naked eye) after the 18weeks of accel-
erated degradation were 60, 70, and 80% HS. The time required
for almost complete degradation of 60, 70, and 80% HS was 8, 14,
and 18weeks, respectively. The polymers with 90 and 100% HS
underwent only partial degradation, the change in sample size and
shape may be a result of shrinkage or softening at 70°C.
In vitro Cytotoxicity Studies (MTT Test)
The effect of the degrading polymer during 18weeks of acceler-
ated degradation on cell viability was determined by aMTT assay.
The polymer samples were sterilized, coated with ECM proteins,
and placed in oven at 70°C for 18weeks. At pre-determined time
points (24 h, 1, 2, 4, 6, 8, 10, 14, and 18weeks), 100 µL of the
degradation solution was removed and a twofold serial dilution
was performed to determine the effect of the eroded polymer
fragments on cell viability. A serial dilution was performed to
determine the dose-dependent effect of the degradation products
on cell viability. The results show that three factors influenced
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FIGURE 1 | A comparison of the physical changes to the polymer observed during degradation at 70°C. Polyurethanes 60, 70 and 80% lost 100% of their
original weight after 8, 14 and 18w, respectively. The weight loss for PU90 and PU100% was negligible.
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FIGURE 2 | The cytotoxicity of the degradation solution during
accelerated degradation. The toxicity of the degradation products was
determined by a MTT test at (A) 1, (B) 8, (C) 14, and (D) 18weeks of
degradation. In each panel the brighter color represents the % cells viability for
100% (undiluted) and lighter color 50% diluted and grey color no degradation
solution (control), respectively.
the cytotoxicity: the dose, the HS percentage, and the degradation
time (Figure 2).
The cell viability was found to be dependent on the amount of
degradation solution that the cells were exposed to. The statistical
analysis comparing the five HS percentages and four experimen-
tal conditions at each time point (repeated-measures two-way
ANOVA) showed that the ECM coating, HS percentage, concen-
tration of degradation products, and the interaction between these
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factors had a significant effect on cell viability (all results were
p< 0.05 or lower at each degradation time point).
The cell viability at exposures to 25, 12.5, 6.3, 3.1, and 1.6%
degradation solution was very similar to the 50% cell viability;
therefore, these values were not shown on the graph. The cell via-
bility ofHUVECafter exposure to 50%of the degradation solution
was similar to that of 1.6% of the degradation solution. The results
shown in Figure 2 only represent the average cell viability after
exposure to 100% of the degradation solution, 50% degradation
solution, and no degradation solution. At exposure to 50% of the
degradation solution, cell viability remained between 100 and 80%
for the duration of 18weeks. The effect of accelerated degradation
on cell viability upon exposure to 100% of the degradation prod-
ucts was dependent on the HS. As the HS percentage increased,
the effect of degradation on cell viability was also increased.
This result was observed at each time point during the 18-week
degradation period. In general, the degradation time also affected
cell viability. For each HS percentage increase the degradation
solution after 24 h was less toxic than the one after 18weeks. For
each PU, the cell viability of HUVEC decreased with degradation
time. There was no significant effect of having ECM coating on
cell viability, presumably due to active sites on the coating being
blocked as a result of strong interaction with PU surface.
The Toxicity of the Degradation Solution Solid
Components
The effect of each component of the degradation solution on
cell viability was determined for the 60% HS sample only. The
degradation solution was centrifuged to isolate the solid particles
from the PBS degradation solution. The cell viability after
exposure to the complete degradation solution (particles+PBS),
the PBS alone and the degradation particles alone was determined
using a MTT test. Both quantitative (MTT test) and qualitative
analysis (visual analysis) methods were used to demonstrate
and/or investigate the effect of each degradation component
(Figure 3) on cell viability.
As shown in Figure 3, the morphology of the HUVEC cells
(form and structure) varied depending on the degradation solu-
tion component that the cells were exposed to. The HUVEC
appearance in the control (no products) was that of a typical
endothelial culture, exhibiting a cobblestone arrangement, as evi-
denced inFigure 3A. This cellmorphologywas also observed after
exposure to the degradation particles only: there were no signs of
apoptosis in this live culture (Figure 3C). After exposure to the
complete degradation solution, theHUVEC cells formed rounded
structures, characteristic of apoptotic cells. The cells completely
detached from the TCPS surface and formed several clusters of
apoptotic cell aggregates (Figure 3B). Apoptotic cells were also
observed in the PBS only sample. The HUVEC in this condition
changed in appearance and conformation; from the characteristi-
cally flat and spread structure of endothelial cells, to a raised and
rounded form (Figure 3D). As highlighted in Figure 3, there was
evidence of degradation particles in the cell culture of both the
complete degradation solution (Figure 3B) and the degradation
particles only sample (Figure 3C).
Figure 3 also shows that the cell viability recorded after expo-
sure to the complete degradation solution was 25 1%, after
FIGURE 3 | Digitally altered representation of the cytotoxicity of
individual degradation components in the degradation solution. The
degradation solution for 60% HS was separated and tested for cytotoxicity.
The morphological changes (and corresponding cell viability) after exposure to
(A) no products (100%), (B) the complete degradation solution (25%),
(C) particles only (95%) and (D) PBS only (44%). The cell viability for the
complete degradation solution (particles+PBS) and PBS alone (PBS) was
statistically lower (=p<0.001) than the particles alone (particles) and the
control (no products). The appearance of degradation particles is highlighted
by the circle and the arrow identifies the apoptotic cells (Bar= 100 µm).
exposure to PBS alone was 44 1% and for particles alone the
viability was 95 4%. The cell viability after exposure to only the
degradation particles was statistically similar to the cell viability
after exposure to the nondegradation solution (no products).
The cell viability after exposure to complete degradation solution
and PBS alone was significantly lower than all other conditions
(p< 0.001 one-way ANOVA).
pH Changes during Accelerated Degradation
The pH of the degradation solution was monitored to determine
whether polymer erosion had an effect on acidity. The results
show that the effect of polymer degradation on pHwas dependent
on the HS percentage. As shown in Figure 4, the pH for 60, 70,
80, and 90% HS was neutral (7.4 0.2) until Week 1, then the pH
decreased to 5.9 0.0, 6.5 0.4, 6.6 0.3, 7.1 0.0, respectively.
The decrease in pH for these polymers continued until Week 8,
with a respective final pH of 5.5 0.2, 5.7 0.1, 6.5 0.3, 6.9
0.1. The pH for 100% HS remained neutral until Week 8, ranging
between 7.4 0.0 and 7.3 0.1.
Growth Curve
HUVEC proliferation on uncoated PU samples was measured
over a 14-day incubation period and compared to the growth on
TCPS. The endothelial cells adhered onto all five PU surfaces as
early as 1 h post-seeding and were observed as mostly spherical
cells. At 48 h post-seeding, the cells had flattened and spread
across the surface. Figure 5 shows that the growth of endothelial
cells on the polymer series exhibited the general growth pattern
of endothelial cells; the proliferation phase was observed between
2 and 8 days, the stationary phase between 8 and 11 days, and the
log phase after 13 days. The proliferation on the PU series showed
a peak of 23.0 1.6 at Day 10 and decreased to 17.0 1.0 after
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FIGURE 5 | Endothelial cell growth on the PU series over time. Compared to TCPS (- - - - blue data points), the PU series (——— black data points) required a
longer time in culture to reach endothelialization.
Day 14 in culture. The endothelial cell growth and proliferation
were similar on both TCPS and PU surfaces; however, endothe-
lialization was delayed on the PU. The endothelial cell adherence
at 24 h and 48 h was similar on both polymers. A difference in
proliferation was demonstrated after 4 days in culture, with a
proliferation rate of around 11 on TCPS, which was not observed
on the PU series until Day 6. The proliferation on TCPS reached a
peak at Day 8, compared to Day 10 on the polymer series. By Day
9, the proliferation on the TCPS began to decrease, whereas the
proliferation on the PU series was still within the stationary phase.
A final proliferation rate of around 17was observed for both TCPS
and the PU series at Day 12 and Day 14, respectively. This result
shows that HUVEC growth on the degradable PU series is similar,
but not identical, to that observed with TCPS.
HUVEC Growth on Extracellular Matrix-Coated
Polyurethane
Cultured HUVEC were seeded on different ECM proteins at a
density of 20,000 cells/cm2, and the proliferation rate was mea-
sured 48 h post-seeding. Figure 6 shows that the effect of an ECM
coating on proliferation was dependent on the type of protein and
the HS percentage of the polymer. The statistical analysis com-
paring the five HS percentages and four experimental conditions
(two-way ANOVA) showed that the coating and HS percentage
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FIGURE 6 | The difference in HUVEC proliferation on collagen (Coll), fibronectin (Fn), collagen+ fibronectin (Coll+Fn) and noncoated (Non) polymer
surfaces of all PUs in the series along with results for TCPS.
had a strongly significant effect on proliferation (p< 0.0001),
however, the interaction between the HS and coating was not
significant. The statistical analysis comparing the effect of an ECM
coating on eachHS percentage individually (Bonferroni post-test)
showed ECM statistical significance with 60% HS samples only.
As shown in Figure 6, the HUVEC proliferation on Coll was
significantly higher than on a Fn coating (p< 0.05). The highest
HUVEC proliferation observed on TCPS, 90 and 100% HS was
on the Coll+ Fn coating, with the respective values being 3.5 0,
3.6 0 and 3.5 1. The highest proliferation observed on 60, 70,
and 80% HS was on a Coll coating, with the respective values
being 3.1 0.0, 2.9 0.1 and 3.2 0.2. For each HS percentage,
the endothelial cell proliferation was similar on the uncoated and
Fn-coated material, and the endothelial cell proliferation on Coll
andColl+ Fnwas also similar. In general, HUVECprefers to grow
on aColl orColl+ Fn coating, when compared to a Fnor uncoated
surface.
Visual Analysis of HUVEC on the Polyurethane
Surface
To provide evidence that a complete endothelialization occurred
on the surface of the PU samples, immunofluorescent microscopy
was used. Endothelial attachment was observed on each 1 cm
round sample, after 2 h in culture, at a seeding density of
20,000 cells/cm2 and complete surface endothelialization was
achieved at 48 h. As shown in Figure 7, the HUVEC exhibited
a cobblestone appearance typical of endothelial cells on the PU
surface. The PU with 80% HS is shown in the figure, the HUVEC
morphology was similar on all samples. After 48 h in culture, the
cells were flat with a round shape and large nuclei.
Discussion
Our previous study demonstrated that the PUs in this series were
very slow to degrade, over a 9-month period under real-time (PBS
FIGURE 7 | Fluorescence microscopy showed that the endothelial
cells had attached, spread and produced a monolayer with a typical
“cobblestone” appearance (Bar=100 µm). The endothelialized PU
surface (80% HS) 48 h post-seeding.
at 37°C) conditions (Sgarioto et al., 2014). The present acceler-
ated degradation study was undertaken to force degradation by
increasing the temperature to 70°C to understand the effect of HS
content on degradation rate and to evaluate toxicity of degradation
products as well as the residual polymer (vanMinnen et al., 2006).
The degradation medium chosen was hydrolytic in nature and
assumed that the higher temperature may only accelerate the
degradation without altering the degradation mechanism.
Considering the chemical composition of the PUs in the
series, a complete degradation of urethane and ester functional
groups would yield 1,6-hexanediamine, isophorone diamine, 1,4-
butanediol from HS degradation and lactic acid and glycolic acid
from the SS. However, due to the relatively slow rate of urethane
degradation, the degradation products may be largely associated
with the SS degradation. It is also equally important to understand
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any toxicity associated with the residual polymer fragments, low
molecular weight oligomers which are not soluble and retained
within the sample.
The results of this study are consistent with those reported in
the literature (Tatai et al., 2007) confirming that PUs with lower
HS content degrades faster than thosewith higherHS. Three of the
polymers in the series completely disintegrated within 18weeks of
accelerated degradation: 60% HS (8weeks), 70% HS (14weeks),
and 80% HS (18weeks). On the other hand, only partial degrada-
tion was observed for polymers 90 and 100% HS with no appre-
ciable weight loss. The polymer samples degraded to form small-
rounded structures atWeek 4, and there was no observable change
in the physical appearance from Week 4 to Week 18, presumably
due to long HS blocks remaining not degraded.
A good understanding of the biocompatibility of materials and
toxicity of compounds generated during degradation is essential
before considering any new material for biomedical applications
(Gunatillake and Adhikari, 2003; Williams, 2008). As the material
degrades not only the physical properties but also the chemical
composition, surface properties and morphology undergo signif-
icant changes. Understanding how the surrounding tissues react
to these changes is critical for the safety of using such materials
in clinical applications. In vitro studies are a first step in this pro-
cess and provide valuable information before conducting detailed
in vivo testing.
As shown in Figure 2, the effect of the degradation products
on cell viability when tested in PBS undiluted was highest for the
fast degrading 60%HS and decreased with increasing HS content.
This tendency was maintained up to 8weeks and the difference
became less significant after that, and in 18weeks the cell viability
was around 40% for all materials. The cells were exposed to seven
different concentrations of degradation products: 100, 50, 25,
12.5, 6.3, 3.1, and 1.6%. As there was no observable difference
for concentrations ranging from 1.6 to 50%, values recorded for
concentrations below 50% were not displayed on the graph. This
apparent lack of dose dependency for concentrations below 50%
dilution may be attributed to this range being below the concen-
tration level of toxicity of these components. In slow degrading
materials the soluble degradation products will continually be
removed from the implant site causing no advertise effect to
surrounding tissues. It should be noted that the undiluted solution
was tested in PBS while other samples were diluted with media.
In most cases, there was a statistically significant difference in
cytotoxicity when cells were exposed to 100% of the degradation
products compared to 50%.
The cell viability of degradation products diluted to 50% was
between 100 and 80% for the duration of 18weeks for all samples,
statistically similar to control PBS solution with no degradation
products. As discussed earlier, the major degradation products of
these PUs are derived from the hydrolysis of the SS based on lactic
and glycolic acids, and this is supported by the observation that
pH decreased to 7.26 for 100%HS and 5.48 for 60%HS (Figure 4)
During the accelerated degradation study, the pH of the degra-
dation solution was not maintained at 7.4 ( 0.2) (van Minnen
et al., 2006) since the pH could not bemeasuredwhilemaintaining
sterility. However, a parallel non-sterile experiment was under-
taken under the same experimental conditions to monitor the pH
changes. Previous reports (Yeomans et al., 1985) have shown that
the normal pH range of umbilical vein blood is 7.35 0.05. Since
the cells used in this study were harvested from the umbilical vein
it can be assumed that their growth would be optimal at a pH of
7.35 0.05. The pH for 60, 70, 80, and 90% HS decreased below
this range after 1 week of accelerated degradation, whereas this
result was not observed with 100% HS until Week 3.
These results suggest that the acidity of the degradation solu-
tion is the primary reason for observed effect on cell viability of
100% degradation solution, reaching levels to cause apoptosis of
HUVEC at 1week for all PUs, except 100% HS (see Figure 4). No
attempt was made to fractionate and identify the compounds and
polymer fragments formed during the degradation. To elaborate
on this further, when the samples had completely disintegrated
into solution (8weeks for 60% HS, 14weeks for 70% HS, and
18weeks for 80%HS), their effect onHUVEC cell viability was the
same, around 40%, for all PUs. However, the cytotoxicity varied
at other time points presumably due to varying concentrations of
degradation products. Similar results have been observed for PUs
by other groups. A study by van Minnen et al. (2006) reported
the accelerated degradation (60°C) of PU foams in distilled water
for 52weeks, and the degradation solution was collected at dif-
ferent time points. Cytotoxicity was observed after 3–5weeks in
the undiluted degradation solution (100% concentration), and
became more cytotoxic toward the end stage of the degradation,
due to accumulation of degradation products, consistent with
what we have observed in this study. In our study, we estimated the
amount of degradation products released to themedium by deter-
mining the polymer weight loss; each week approximately 0.3, 0.2,
and 0.1mg/mL, for 60, 70, and 80% HS, respectively released to
the degradation solution. These results confirm that erosion of
the polymer increases the concentration of degradation products
with time; however, under in vivo conditions it is unlikely that
soluble degradation products are concentrated at implant site
as the body can excrete those from the site, except where large
volume implants are involved producing high concentration of
degradation products.
Most polyester PU degradation studies show that PUs degrade
faster in in vivo conditions compared to in vitro developed to
simulate a biological environment (Zhang et al., 2002; Adhikari
et al., 2008). Zhang et al. (2002) found the in vivo degradation
rate of PU for subcutaneous implantation in rats was three times
faster than in vitro. This study did not undertake in vivo analysis
on the biodegradation of this polymer series, however, there is
literature on the degradation behavior of PUs in different in vivo
conditions (Bruin et al., 1990; Saad et al., 1997; Adhikari et al.,
2008; vanMinnen et al., 2008). An in vivoPUdegradation study by
vanMinnen et al. (2008) found no observable toxicity issues when
PU foams were implanted subcutaneously in rats and rabbits.
After 3 years, the results indicated near complete resorption of
the PU foam with no observable cytotoxicity caused by either the
degrading polymer or its degradation products. During the early
stages of degradation, the number of macrophages and giant cells
increased, then gradually decreased over time. The implant was
completely resorbed, after 3 years, in vivo. Although this study did
not outline the nature of the degradation products and how they
were absorbed/released from the implant site, it is one of only a
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few studies that have documented the longer-term degradation of
a PU implant, demonstrating near complete degradation.
To ascertain whether the residual particulate matter released to
the degradation medium contributes to cell viability, the solution
from 60%HS degradation after 18weeks was centrifuged to sepa-
rate solid degradation particles. The cell viability after exposure
to (B) the complete degradation solution was 25 1%, (D) the
PBS alone was 44 1% and (C) the degradation particles alone
was 95 4% (Figure 3). These results suggest that the observed
effect on cell viability after exposure to the degraded solution is not
caused by the degradation particles themselves. The large-eroded
polymer fragments visible in the degradation solution (Figure 3)
do not affect endothelial cell viability when suspended in media.
The cell viability was mostly affected by the PBS, which would
suggest that the acidic pH of the PBS was the biggest inducer of
apoptosis. There is also a 19% significant difference (p< 0.001) in
the cell viability after exposure to the PBS alone and the original
degradation solution with PBS plus degradation products. This
difference could have been caused by the presence of soluble
fragments produced during the degradation of the SS, which may
have caused cytotoxicity. These molecules would have also been
evident in the “particle only” sample but it would have had little
effect as the number of particles to the volume of media (which
the particles were re-suspended in) would have been too high to
elicit an effect. This result showed that the large-eroded polymer
fragments themselves are nontoxic when diluted in a nutrient
rich media suggesting that in vivo, the products produced during
degradation of this polymer series would be nontoxic to the cells
surrounding the cardiovascular stent.
Previous research on the present PU series has also shown that
thematerials surface has an excellent ability to support endothelial
cell growth and retention (Sgarioto et al., 2014). There are also
many other in vitro cell attachment, proliferation, and cytotoxicity
studies that have shown that biodegradable PUs with a wide
range of chemical compositions, have acceptable cytocompatibil-
ity. Several studies have reported endothelial cells (Yeomans et al.,
1985; Guan et al., 2002, 2004; Zhang et al., 2002; Gunatillake and
Adhikari, 2003; Li, 2007; Tatai et al., 2007; Adhikari et al., 2008;
Williams, 2008; Laschke et al., 2009; Li et al., 2009) chondrocytes
(Saad et al., 1999; Chia et al., 2006; Karbasi, 2009; Adhikari et al.,
2010; Bonakdar et al., 2010) osteoblasts (Wang et al., 2000; Zhang
et al., 2000; Bonzani et al., 2007; Hill et al., 2007; Schlickewei et al.,
2007; Hafeman et al., 2008), fibroblasts (Ganta et al., 2003; Harris
et al., 2006; Guan et al., 2007; Henry et al., 2007; Choi et al., 2008;
Craciunescu et al., 2008; Fromstein et al., 2008; Nieponice et al.,
2008; Rechichi et al., 2008; Raghunath et al., 2009; Wang et al.,
2009; Parrag and Woodhouse, 2010) and stem cells (Fromstein
et al., 2008; Nieponice et al., 2008; Li et al., 2009; Raghunath et al.,
2009; Wang et al., 2009) attachment, growth and proliferation on
different types of biodegradable PUs. To further investigate the
growth of endothelial cells on the PUs, the growth curve pattern
was compared to TCPS. Tissue culture polystyrene is often used
as a control for many polymer and tissue culture studies (Saad
et al., 1997; Guan et al., 2002; Ganta et al., 2003; Choi et al.,
2008; Greenwood et al., 2010) as it is known that cells grow well
on TCPS.
As shown inFigure 5, the cell adherence and proliferation study
of the PU series exhibited a similar growth pattern to that of TCPS,
except endothelialization of PU was slow, needing 28 h more than
TCPS. This difference may be attributed to the difference in sur-
face hydrophobicity; the average PU contact angle was 80° com-
pared to 71.8° for TCPS. Vogler (1999) reports hydrophilic mate-
rials better support and encourage cell attachment and growth
compared to hydrophobicmaterials. Our previous study (Sgarioto
et al., 2014) on ECM-coated TCPS found that a double coating
of Coll+ Fn exhibited a significantly higher proliferation and
migration compared to a single Coll or Fn coating. In this perspec-
tive, the surface of the polymers was coated with three different
coatings (Coll, Fn and Coll+ Fn) to improve cell attachment and
retention. Figure 6 shows that HVUEC proliferation was highest
on either aColl or Fn coating, when compared to other coatings on
the same HS percentage. The highest proliferation of endothelial
cells was observed on TCPS, 90 and 100% HS with a coating of
Coll+ Fn, whereas the highest proliferation observed on 60, 70,
and 80%HSwas on aColl coating. The only significant differences
between protein coating were observed with TCPS and 60% HS
(Figure 6). In general, across all HS percentages, an ECM coating
did not significantly improve HUVEC proliferation.
It appears from this study, along with previous studies on
this PU series that the surface of this polymer series does not
require surfacemodification tomaintain cell adhesion. The results
showed that the effect of an ECM coating is influenced by the
underlying polymer base, and is likely to be related to the surface
structure and/or contact angle of the different polymers. The con-
tact angle of the PU series was around 80°, which is considered as
hydrophobic compare to TCPS 71.8° which is considered as being
hydrophilic (Bahulekar et al., 1998; Vogler, 1999). This difference
in hydrophobicity/hydrophilicity will affect the ability of cells to
interact and bind to these materials. It will also affect the ability
of proteins to adsorb to the surface of both the PU and TCPS.
Although some-what speculative, it is possible that since the PU
series is hydrophobic, Coll and Fn deposition and adsorption
would occur more strongly to the PU surface through hydrogen
bonding. This may cause the cell binding sites on the proteins to
be immobilized and are thus unavailable for interaction with the
HUVEC. In the case of TCPS, the deposition and adsorption of
Coll and Fn may be less strong, therefore the cell-binding sites
are still available for attachment by HUVEC. The results suggest
that differences in HUVEC proliferation on ECM-coated PU
compared to the results observed on TCPS is associated with dif-
ferences in hydrophobicity/hydrophilicity and surface functional
groups between the two polymers. It is clear from the results of this
study that HUVEC proliferation and growth is influenced by the
surface structure of the polymer. The cytocompatibility question
that cannot be answered from this investigation is whether or not
the by-products frompolymer degradationwill be toxic to inflam-
matory cells, in particular phagocytes (including macrophages).
Theoretically, the eroded polymer fragments in the arterial wall
will be ingested bymacrophages and subsequently excreted by the
body. If polymer fragments enter the bloodstream they will be
ingested by monocytes. The roles of the macrophage/monocyte
are both nonspecific and specific phagocytosis of any foreign
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material when it comes in contact with, including bacteria, cellular
debris and synthetic particles (Doshi and Mitragotri, 2010).
In summary, the accelerated study was performed to under-
stand the hydrolytic degradation of highmodulus PUs. The results
showed that the time required for complete degradation of this PU
series was dependent on the HS percentage. Only three polymers
completely degraded/disintegrated during the 18 week; 60, 70,
and 80% HS. The MTT assay demonstrated that the degradation
products when tested undiluted showed an effect on cell activity
but when diluted to 50% degradation products and below did not
affect HUVEC cell proliferation, suggesting concentration thresh-
old below which no apparent effect. The degradation products
were diluted in media (1:2 dilution) and the cell viability was
around 80% for the duration of the accelerated degradation study.
At 18weeks, PUs that had completely degraded into solution had
a similar effect on HUVEC cell activity, irrespective of their HS
percentage. This result suggests that cell viability was not caused
by the actual chemical components (oligomers or monomers)
produced during degradation, but instead the accumulation of
these acidic products in the degradation solution. The results
showed that the growth pattern of the PU series was similar to
that observed with TCPS showing that these polymers have excel-
lent surface characteristics for HUVEC growth and proliferation.
For most of the polymers in the series, the degradation solution
became acidic over time affecting HUVEC activity. As the HS
decreased, the pH decreased due to accumulation of SS degrada-
tion products. The results from this study suggest that themixture
of degradation particles produced during the degradationmay not
be toxic, however, it is necessary to undertake in vivo studies to
determine whether or not the body has the ability to buffer the
acidity caused during degradation as well as to metabolize and
excrete the degradation products.
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